Current Clinical Trials

Department: Cardiology
Diagnosis: Cardiac - Acute Coronary Syndrome
Sub-Investigator(s):
Sponsor: Sanofi Aventis
Indentifier #: NCT01663402
Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of SAR236553/REGN727 on the Occurrence of Cardiovascular Events in Patients Who Have Recently Experienced an Acute Coronary Syndrome (Odyssey SA_EFC11570)
Department: Cardiology
Diagnosis: Cardiac - Hyperlipidemia
Sponsor: Pfizer
Indentifier #: NCT01975376
Title: B1481022: Phase 3 Multi Center, Double Blind, Randomized, Placebo Controlled, Parallel Group Evaluation Of The Efficacy, Safety, And Tolerability Of Pf-04950615, In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects
Department: Cardiology
Diagnosis: Cardiac - Arrhythmia
Principal Investigator: Venkatesh M.D., Govindarajan
Sub-Investigator(s):
Sponsor: Janssen
Indentifier #: NCT01701817
Title: Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II ORBIT-AF II IRB ID [4130C-101]
Department: Cardiology
Diagnosis: Cardiac - Hyperlipidemia
Sponsor: Pfizer
Indentifier #: NCT01975389
Title: B1481038 PHASE 3 MULTI-CENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL GROUP EVALUATION OF THE EFFICACY, SAFETY, AND TOLERABILITY OF PF-04950615, IN REDUCING THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN HIGH RISK SUBJECTS
Department: Cardiology
Diagnosis: Cardiac - Coronary Artery Disease
Principal Investigator: Kaluski MD, Edo
Sub-Investigator(s):
Sponsor: Janssen
Indentifier #: NCT01830543
Title: An Open-label, Randomized, Controlled, Multicenter Study Exploring Two Treatment Strategies of Rivaroxaban and a Dose-Adjusted Oral Vitamin K Antagonist Treatment Strategy in Subjects With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention, PIONEER AF-PCI